"The voice for cancer physicians and their patients in Massachusetts."

  • 25 Feb 2019 10:54 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Read full press release

  • 05 Feb 2019 1:50 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved the expanded use of ibrutinib (imbruvica; Pharmacyclics) in combination with obinutuzumab for adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). Read full press release.

  • 15 Jan 2019 2:45 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved cabozantinib (Cabometyz; Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

  • 14 Jan 2019 3:27 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved gilteritinib (Xospata; Astellas) for treatment of adult patients who have relapsed or refractory acut myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA approved test. Read full press release.

  • 14 Jan 2019 3:24 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved atezolizumab (Tecentriq; Genentech) in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. Read full press release.

  • 14 Jan 2019 3:08 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved romiplostim (Nplate; Amgen) for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Read full press release

  • 14 Jan 2019 3:02 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Read full press release.

  • 14 Jan 2019 2:26 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Read full press release.

  • 14 Jan 2019 2:02 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ravulizumab-owvz (Ultomiris; Alexion Pharmaceuticals, Inc.) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Read full press release

  • 21 Sep 2018 10:55 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ibrutinib (Imbruvica; Pharmacyclics) plus rituximab (Rituxan) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM). Read full press release. 

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software